Роль адъювантного химиолучевого лечения в комплексной терапии рака тела матки II - III стадии

Автор: Иксанова А.Р., Крейнина Ю.М.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 2 т.15, 2015 года.

Бесплатный доступ

Аннотация В работе представлен обзор литературных данных, касающихся современного состояния проблемы лечения больных раком тела матки. Отмечено значимое снижение онкологических результатов у пациенток со II-III стадией заболевания, приведены результаты мета-анализов и ряда мультицентровых рандомизированных исследований последних лет, демонстрирующих положительное влияние адъювантной лучевой и химиотерапии в различных режимах на выживаемость больных раком тела матки с неблагоприятным прогнозом, аргументирована необходимость исследования влияния на исход лечения у больных данной категории профилактического облучения нижней группы парааортальных лимфоузлов в сочетании с химиотерапией в таксано-платиновом режиме.

Еще

Рак тела матки, неблагоприятный прогноз, химиолучевое лечение, лучевая терапия, парааортальные лимфоузлы

Короткий адрес: https://sciup.org/14955486

IDR: 14955486

Список литературы Роль адъювантного химиолучевого лечения в комплексной терапии рака тела матки II - III стадии

Бохман Я. В. Руководство по онкогинекологии. Санкт Петербург: Издательство Фолиант. 2002. 542с.
Каприн А. Д., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2013 году. Москва: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. 2014. 235с.
Крикунова Л. И. Лучевая терапия рака матки.//Практическая онкология. 2004. Т. 5. № 1. 2004. C. 33 -40.
Моисеенко В. М. Практические рекомендации по лекарственному лечению злокачественных опухолей (RUSSCO). Москва: Общество онкологов-химиотерапевтов. 2013. 384с.
Мустафина Е. А. Рак тела матки II стадии (клинико-морфологические факторы прогноза и лечение): Дис. … к-та. мед. наук: 14.00.14/Российский онкологический научный центр РАМН. 2005. 136c.
Табакман Ю. Ю. Рак эндометрия, руководство для врачей. Москва: Практическая медицина. 2009. 172с.
Титова В. А., Столярова И. В., Крейнина Ю. М. Современные технологии комплексного лечения рака эндометрия. Научно-практическое издание.//Санкт Петербург: Издательство Фолиант. 2012. 168с.
ASTEC/EN 5 study group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.//Lancet. 2009. 373. N 9658. P. 137-146.
Cho H, Nam BH, Kim SM et al. A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer. A Korean Gynecologic Oncologic Group Study.//Int J Radiat Oncol Biol Phys. -2014. -Vol. 90, N 1. -P. 140-146.
Choi EC., Kim JH., Kim OB. et al. Postoperative radiotherapy for endometrial cancer//Rad Oncol J. 2012. V. 30, N 3. P. 108 -116.
Colombo N., Preti E., Landoni F. et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Ann Oncol. 2013. V. 24. P. 33-38. Suppl. 6.
Creutzberg CL., van Putten WL., Koper PC. et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage 1 endometrial carcinoma: multicentre randomized trial. PORTEC study group. Post operative radiation therapy in endometrial carcinoma.//Lancet. 2000. V. 355. N. 9213. P. 1404-1411.
Dewdney SB., Mutch DG. Evidence-based review of the utility of radiation therapy in the treatment of endometrial cancer.//Women's Health. V. 6. N 5. 2010. P. 695-704.
Fleming GF., Brunetto VL., Cella D. et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.//J Clin Oncol. 2004, V. 22. N 11. P. 2159 -2166.
Fleming GF., Filiaci VL., Bentley RC et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.//Ann Oncol. 2004, V. 15 N. 8. P. 1173 -1178.
Greven K., Winter K., Underhill K. et al. Radiation Therapy Oncology Group. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.//Int J Radiat Oncol Biol Phys 2004. V. 59. N 1. P. 168 -173.
Hoekstra AV., Kim RJ., Small WJ. et al. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.//Gynecol Oncol. 2009. V. 114. N 2. P. 273 -278.
Hogberg T., Rosenberg P., Kristensen G. et al. A randomized Phase III study on adjuvant treatment with radiation ± chemotherapy in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991).//J Clin Onol ASCO. Annual Meeting Proceedings. 2007. V. 25. N. 18. Suppl. 5503.
Hogberg T., Signorelli M., de Oliveira CF. et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies.//Eur J Cancer. 2010. V. 46. N 13. P. 2422 -2431.
Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.//J Clin Oncol. -2001. -Vol. 19, N 20. -P. 4048-4053.
Hwang SM., Chay DB., Kim S. et al. Concurrent chemoradiation with paclitaxel in high-risk endometrial cancer patients after surgery: A Korean Gynecologic Oncology Group study.//Gynecol Oncol. 2014. V. 133. N. 2 P. 207. suppl. 140.
Jhingran AA., Ramondetta LM., Bodurka DC. et al. Prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.//Gynecol Oncol. 2013. V. 129. N 2. P. 304-309.
Keys H.M., Roberts JA., Brunetto VL. et al. A Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group Study.//Gynecol Oncol. 2004. V. 92. N 3. p. 744-751.
Kim S., Wu H., Lee H. et al. Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma.//Cancer Res Treat. 2006. V. 38. N 3. P. 133 -138.
Klopp A., Jhingran A., Ramondetta L. et al. Node-positive adenocarcinoma of the endometrium: Outcome and patterns of recurrence with and without external beam irradiation.//Gynecol Oncol. 2009. V. 115. N 1. P. 6 -11.
Klopp A., Smith BD., Alektiar K. et al. The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation Oncology evidence-based guideline.//Pract Radiat Oncol. 2014. V. 4. N 3. P. 137-144.
Kong A., Johnson N., Kitchener HC. et al. Adjuvant Radiotherapy for Stage I Endometrial Cancer: An Updated Cochrane Systematic Review and Meta-analysis.//J Natl Cancer Inst. 2012. V. 104. N 21. P. 1625-1634.
Maggi R., Lissoni A., Spina F. et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial.//Br J Cancer. 2006. V. 95. N 3. P. 266 -271.
Martinez AA., Weiner S., Podratz K. et al. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation.//Gynecol Oncol. 2003. V. 90. N 3. P. 537 -46.
Miao J.W., Deng XH. High-risk endometrial cancer may be benefit from adjuvant radiotherapy plus chemotherapy.//Chin J Cancer Res. 2012. V. 24. N 4. P. 332 -339.
Milgrom SA., Kollmeier MA, Abu-Rustum NR. et al. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.//Gynecol Oncol. 2013. V. 130. N 3. P. 436-440.
Morrow СP., Bundy BN., Kurman RJ. et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study//Gynecol Oncol. 1991. V. 40. N 1. P. 55 -65.
Mundt A.J., McBride R., Rotmensch J. et al. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy.//Int J Radiat Oncol Biol Phys. 2001. V. 50. N 5. P. 1145 -1153.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines In Oncology Uterine Neoplasms. Version 2.2015.//URL:http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
Nomura H., Aoki D., Takahashi F. et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).//Ann Oncol. 2011, V. 22 N 3. P. 636 -642.
Nout RA., Smit VT., Putter H. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomized trial//Lancet. 2010. V. 375. N 9717. P. 816-823.
Park HJ., Nama EJ., Kim S. et al. The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis.//Eur J Obstet Gynecol Reprod Biol. 2013. V. 170. N 1. P. 39-44.
Randall ME., Filiaci VL., Muss H. et al. Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma. A Gynecologic Oncology Group Study.//J Clin Oncol. 2006. V. 24. N 1. P. 36 -44.
Secord AA., Havrilesky LJ., Bae-Jump V. et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.//Gynecol Oncol. 2007. V. 107. N 2. P. 285-291.
Secord AA., Havrilesky LJ, O’Malley DM. et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.//Gynecol Oncol. 2009. V. 114. N 3. P. 442-447.
Secord AA., Geller MA., Broadwater G. et al. A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.//Gynecol Oncol. 2013. V. 128. N 1. P. 65-70.
Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013.//CA Cancer J Clin. 2013. V. 63. N 1. P. 11 -30.
Sorbe B., Nordstrom В., Maenpaa J. et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study.//Int J Gynecol Cancer. 2009. V. 19. N 5. P. 873-878.
Susumu N., Saga S., Udagawa Y. et al. Randomized phase III trial of pelvic radiotherapy versus cisplatinbased combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study.//Gynecol Oncol. 2008. V. 108. N 1. P. 226 -233.
Sutton G., Axelrod JH., Bundy BN. et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol.2005. V. 97. N 3. P. 755 -763.
Tornos C., Silva EG., el-Naggar A. et al. Aggressive stage I grade 1 endometrial carcinoma.//Cancer. 1992. V. 70. N 4. P. 790 -798.
Wen Q., Shao Z., Yang Z. Concomitant paclitaxel plus carboplatin and radiotherapy for high-risk or advanced endometrial cancer.//Int J Gynecol Cancer. 2013. V. 23. N 4. P. 685 -689.

Еще

Статья обзорная